Showing 1,721 - 1,740 results of 3,019 for search '"Tân An"', query time: 0.07s Refine Results
  1. 1721
  2. 1722
  3. 1723
  4. 1724
  5. 1725
  6. 1726

    Non-Luminal Disease Score for Everolimus in Patients with Hormone Receptor‑positive and Human Epidermal Growth Factor Receptor 2-Negative Advanced Breast Cancer: A Mult... by Tan Y, Jiang H, Tian X, Ma F, Wang J, Zhang P, Xu B, Fan Y, Zhao W

    Published 2025-01-01
    “…Yujing Tan,1,* Hanfang Jiang,2,* Xinzhu Tian,1,* Fei Ma,1 Jiayu Wang,1 Pin Zhang,1 Binghe Xu,1 Ying Fan,1 Weihong Zhao3 1Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, 100021, People’s Republic of China; 2Key Laboratory of Carcinogenesis and Translational Research (Ministry of Education), Department of Breast Oncology, Peking University Cancer Hospital & Institute, Beijing, 100142, People’s Republic of China; 3Department of Medical Oncology, Chinese PLA General Hospital, Beijing, 100853, People’s Republic of China*These authors contributed equally to this workCorrespondence: Ying Fan; Weihong Zhao, Email fanying@cicams.ac.cn; zhaowh0818@163.comPurpose: This study aims to explore the role of the non-luminal disease score (NOLUS) for everolimus in patients with hormone receptor-positive and human epidermal growth factor receptor 2-negative (HR+/HER2-) advanced breast cancer (ABC).Methods: NOLUS has previously been established as an algorithm: NOLUS (0– 100) = − 0.45 × ER(%) − 0.28 × PR(%) + 0.27 × Ki67(%) + 73. …”
    Get full text
    Article
  7. 1727
  8. 1728
  9. 1729
  10. 1730
  11. 1731
  12. 1732
  13. 1733
  14. 1734
  15. 1735
  16. 1736
  17. 1737
  18. 1738
  19. 1739
  20. 1740